How Long Does Ozempic Work for Weight Loss?

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The honest answer has two halves. Semaglutide keeps working for as long as it is taken — the trial data show weight curves still separating from placebo at 68 and 72 weeks, with no evidence of pharmacological tolerance — and it stops working when it is stopped, with randomised withdrawal trials consistently showing substantial regain. The other half of the answer is that Ozempic is not approved for weight loss at all. It is indicated for glycemic control, cardiovascular risk reduction and kidney outcomes in adults with type 2 diabetes. Wegovy is the semaglutide product carrying the weight-management indications.

What the Long Trials Showed

STEP 1 ran 68 weeks in 1,961 adults and reported a mean body weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Study 8 in the Wegovy label ran 72 weeks in 1,407 participants and reported −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9%.

In both, the curves were still diverging late in the trial. That is the key structural fact: the effect did not plateau at eight weeks or at six months, which is why judging the medication early is misleading.

The cardiovascular outcomes trial reported in the Wegovy label ran considerably longer, with mean anthropometric changes reported at week 104 — a body weight change of −9.4 kg with semaglutide versus −0.93 kg with placebo in a population selected for cardiovascular disease rather than for obesity trial criteria.

Appetite Effects Arrive Long Before Weight Change

Reduced appetite and earlier fullness typically appear within the first weeks, because those follow directly from delayed gastric emptying and central appetite signalling. Weight change follows the cumulative energy deficit, which takes considerably longer to become visible.

That mismatch is the source of most early disappointment. Someone who feels a dramatic appetite change in week two and then sees a modest scale change in week six concludes the medication is failing, when the labeled escalation has not even reached a maintenance strength yet.

The escalation itself is deliberately gradual, and its purpose is tolerability rather than efficacy. Nausea, vomiting, diarrhea, abdominal pain and constipation are the most common adverse reactions and the most common reason people stop early.

Plateaus Are Physiology, Not Tolerance

Weight loss slows as it progresses on any intervention. Resting energy expenditure falls with body mass, appetite-regulating signals adapt, and the same energy deficit produces a smaller weekly change than it did at the start.

This is not the medication losing potency. There is no established pharmacological tolerance to GLP-1 receptor agonists in the sense of a receptor becoming unresponsive, and the trial data do not show the effect washing out over the study period.

What to do about a genuine plateau — hold, reassess nutrition and activity, review other medications, or consider a labeled strength change — is a clinical judgement your prescriber makes. It is not something to resolve by increasing your own dose, and the FDA has documented serious adverse events associated with dosing beyond approved labels.

Stopping Reverses It

Randomised withdrawal designs across this class consistently show substantial weight regain after discontinuation, with cardiometabolic improvements reversing alongside the weight. Recent reviews frame this as disease recurrence rather than treatment failure, consistent with obesity being a chronic, relapsing condition.

The Wegovy indication reflects that framing directly: it is written as reducing excess body weight and maintaining weight reduction long term. Maintenance is inside the approved use rather than an optional extension of it.

Real-world discontinuation is high, driven by cost, coverage changes, supply interruptions and adverse effects. That is the most common reason a course "stops working" — not the pharmacology, but the interruption.

What Continued Treatment Is Actually Buying

Beyond weight, the outcome data cover cardiovascular events, kidney outcomes in type 2 diabetes, obstructive sleep apnea for tirzepatide, and liver histology in MASH for semaglutide under accelerated approval. Several of those benefits are indication-defining rather than incidental.

For someone whose primary concern is cardiometabolic risk rather than the scale, that matters. The relevant question at a plateau may be whether risk markers have improved, not whether the weekly weight change has stalled.

It also reframes the duration question. These labels increasingly read like those of chronic disease medications, and asking how long a chronic disease medication "works" is a different question from asking how long a course of treatment lasts.

Setting Realistic Expectations From the Start

Plan on a horizon of a year or more before judging the outcome, because that is the timeframe the evidence was generated over. Plan for maintenance rather than an endpoint. Plan the funding route before starting, because a lapse mid-course behaves like a deliberate stop.

Track more than weight — blood pressure, glycemic markers where relevant, symptom burden, and whether nutrition remains adequate now that total intake has fallen. Protein adequacy and resistance training matter for lean mass preservation.

And keep the product distinction straight. Ozempic, Wegovy, Rybelsus, Ozempic tablets, Wegovy tablets, Mounjaro, Zepbound and Foundayo are different approvals with different indications, and a compounded preparation is not any of them.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does semaglutide stop working after a few months?

There is no established pharmacological tolerance to GLP-1 receptor agonists. STEP 1 ran 68 weeks and Study 8 in the Wegovy label ran 72 weeks, with weight curves still separating from placebo late in both. Weight loss does slow as it progresses, because resting energy expenditure falls with body mass, but that is physiology rather than the medication losing potency.

How quickly should I expect to see results?

Appetite effects typically appear within the first weeks because they follow directly from delayed gastric emptying and central appetite signalling. Weight change lags, because it reflects a cumulative energy deficit, and the labeled escalation is deliberately gradual. The pivotal trials measured their primary outcomes at 68 and 72 weeks, which is the realistic horizon.

What happens when I stop taking it?

Randomised withdrawal trials across this class consistently show substantial weight regain after discontinuation, with cardiometabolic improvements reversing alongside. Recent reviews describe this as disease recurrence rather than treatment failure. The Wegovy indication is written to include maintaining weight reduction long term, which signals that maintenance is part of the approved use.

Is Ozempic approved for weight loss?

No. Ozempic is indicated for glycemic control in adults with type 2 diabetes, for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for reducing kidney outcomes in adults with type 2 diabetes and chronic kidney disease. Wegovy is the semaglutide product carrying the weight-management indications.

Should I increase my dose if progress slows?

Not on your own initiative. Dosage decisions belong to your prescriber, who is weighing tolerability, your other medications and your full clinical picture. The FDA has received adverse event reports, some involving hospitalization, that may relate to dosing beyond what appears in approved labels — larger single doses, more frequent dosing, or faster escalation.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.